Novatis developed this drug in the 1990s. In the years since then the price of the drug has increased astronomically. Novartis must have recovered their research costs long ago, but the price just keeps rising. The cost rose from approximately $6000 for a 90 day supply in 2001 to $19,000 now. Patients with CML leukemia are dependent on the drug to keep them alive. Our US Representatives should work with FDA to pressure Novartis to reduce the cost of Gleevec.